Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trade marked its repurposed Exenatide as Presendin™. Following a successful Phase II clinical trial in May 2020, the Company will now progress Presendin™ into a Phase III registration study in IIH.